Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice.
Cytokines interact not only with membrane anchored receptors, but also with specific soluble receptors which circulate in the bloodstream. In general, soluble cytokine receptors such as soluble tumor necrosis factor receptor, soluble interleukin 1 receptor, and soluble interleukin 4 receptor compete with their membrane-bound counterparts for the ligands and therefore act as antagonists. In contrast, soluble receptors for cytokines of the interleukin-6 (IL-6) family complex with their ligands act agonistically. Interestingly, the complex of IL-6 and the soluble interleukin 6 receptor (sIL-6R) activates target cells that do not express the membrane-bound IL-6R and therefore cannot respond to IL-6. To identify cellular responses that are due to IL-6/sIL-6R but not to IL-6 alone, IL-6/sIL-6R double-transgenic mice were generated and compared with IL-6 single-transgenic mice. IL-6/sIL-6R transgenic mice develop a severe phenotype showing 1) marked hepatocellular hyperplasia frequently surrounded by peliosis and necrosis, 2) significant acceleration and aggravation of plasmacytoma formation, and 3) excessive activation of extramedullary hematopoiesis in spleen and liver followed by a subsequent increase of all cellular components in the peripheral blood. These in vivo data suggest that the sIL-6R recruits primarily unresponsive cell populations such as hematopoietic progenitor cells and hepatocytes to IL-6-induced proliferation, but also enhances the known mitogenic effect of IL-6 on plasma cells and thereby contributes to plasmacytoma formation.
Schirmacher
P
P
Institute of Pathology, University of Mainz, Germany.
Peters
M
M
Ciliberto
G
G
Blessing
M
M
Lotz
J
J
Meyer zum Büschenfelde
K H
KH
Rose-John
S
S
D000818:Animals; D001835:Body Weight / Q000235:genetics; D006411:Hematopoiesis, Extramedullary / Q000235:genetics / Q000276:immunology / Q000502:physiology; D006801:Humans; D006965:Hyperplasia; D015850:Interleukin-6 / Q000235:genetics / Q000502:physiology*; D008099:Liver / Q000276:immunology / Q000473:pathology*; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology*; D051379:Mice; D008822:Mice, Transgenic; D009336:Necrosis; D009929:Organ Size / Q000235:genetics; D010954:Plasmacytoma / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D019947:Receptors, Interleukin-6 / Q000235:genetics / Q000502:physiology*; D013154:Spleen / Q000276:immunology / Q000473:pathology
D015850:Interleukin-6; D019947:Receptors, Interleukin-6